Aktuelle smitsomme sygdomme
Søgeord (prep) valgt.
3 emner vises.
Vita W Jongen, Daniela Bezemer, Ard van Sighem, Anders Boyd, Casper Rokx, Karin Grintjes, Aafke Cents-Bosma, Eline Op de Coul, Birgit van Benthem, Annemarie Wensing, Ferdinand WNM Wit, Marc van der Valk and on behalf of the ATHENA national observational HIV cohort
Eurosurveillance latest updates, 20.09.2024
Tilføjet 20.09.2024
BackgroundIn the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known. AimWe assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands. MethodsData on prior PrEP use between 1 January 2018 and 31 December 2022 were available from the Dutch national ATHENA cohort. We assessed proportion of prior PrEP use, detected PrEP associated RAMs and assessed potential onward transmission of RAMs between 2010 and 2022 using a maximum likelihood tree. ResultsData on prior PrEP use were available for 583/1,552 (36.3%) individuals, with 16% (94/583) reporting prior PrEP use. In 489 individuals reporting no prior PrEP use, 51.5% did not use PrEP due to: low HIV-risk perception (29%), no access (19.1%), personal preference (13.1%), and being unaware of PrEP (19.1%). For PrEP users, 13/94 (13.8%) harboured a M184V/I mutation, of whom two also harboured a K65R mutation. In people with a recent HIV infection, detection of PrEP RAMs increased from 0.23% (2/862) before 2019 to 4.11% (9/219) from 2019. We found no evidence of onward transmission of PrEP RAMs. ConclusionThe prevalence of PrEP-associated RAMs has increased since PrEP became available in the Netherlands. More widespread access to PrEP and retaining people in PrEP programmes when still at substantial risk is crucial to preventing new HIV infections.
Læs mereMedscape Infectious Diseases, 17.09.2024
Tilføjet 17.09.2024
The UK government has ordered more than 150,000 doses of Bavarian Nordic\'s mpox vaccine to boost its preparedness against a new form of the virus currently spreading in... Reuters Health Information
Læs mereFlorian Gehre, Eric Nzeyimana, Hakim Idris Lagu, Emmanuel Achol, Julien A Nguinkal, Eric Kezakarayagwa, Théogene Ihorimbere, Néhémie Nzoyikorera, Francine Kabatesi, Marie-Noelle Uwineza, Abdi Roba, Millicent Nyakio Ndia, John Ndemi Kiiru, Gwokpan Awin Nykwec, Isaac Gatkuoth Chot Moun, Mamdouh A Aguer, James A Maror, Gregory Wani Dumo, Michael Losuba, Lul Lojok Deng, Neema Omari, Grace Ochido, Aryse Martins Melo, Peter Bernard Mtesigwa Mkama, Edna Mgimba, Monica Fredrick Francis, Lawrence A Mapunda, Alex Magesa, Nyambura Moremi, Godfrey Pimundu, Tonny Muyigi, Susan Ndidde Nabadda, Emmanuel Kabalisa, Isabelle Mukagatare, Daniel Mukadi-Bamuleka, Erick Ntambwe Kamangu, Jürgen May and Muna Affara
Eurosurveillance latest updates, 30.08.2024
Tilføjet 30.08.2024
The East African Community (EAC) is experiencing an unprecedented, emerging mpox outbreak since July 2024 in five of eight partner states. We highlight rapid regional response measures, initiated August 2024 coordinated by EAC: field deployment of six mobile laboratories in Burundi, Rwanda, Uganda, Tanzania, Kenya, South Sudan to high-risk areas, donation of one mobile laboratory to Democratic Republic of the Congo and genomic monkeypox virus (MPXV) surveillance support. These interventions aim to limit local mpox spread and support international containment.
Læs mere